{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:25:44Z","timestamp":1780377944543,"version":"3.54.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01 DA037826"],"award-info":[{"award-number":["K01 DA037826"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 DA017072"],"award-info":[{"award-number":["K24 DA017072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA041953"],"award-info":[{"award-number":["R21 DA041953"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA0315940"],"award-info":[{"award-number":["R01 DA0315940"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["RR19895"],"award-info":[{"award-number":["RR19895"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["RR029676"],"award-info":[{"award-number":["RR029676"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) treatment as prevention (TasP) strategies can contribute to HCV microelimination, yet complimentary interventions such as opioid agonist therapies (OAT) with methadone or buprenorphine and syringe services programs (SSPs) may improve the prevention impact. This modeling study estimates the impact of scaling up the combination of OAT and SSPs with HCV TasP in a network of people who inject drugs (PWID) in the United States.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using empirical data from Hartford, Connecticut, we deployed a stochastic block model to simulate an injection network of 1574 PWID. We used a susceptible-infected model for HCV and human immunodeficiency virus to evaluate the effectiveness of several HCV TasP strategies, including in combination with OAT and SSP scale-up, over 20 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At the highest HCV prevalence (75%), when OAT coverage is increased from 10% to 40%, combined with HCV treatment of 10% per year and SSP scale up to 40%, the time to achieve microelimination is reduced from 18.4 to 11.6 years. At the current HCV prevalence (60%), HCV TasP strategies as low as 10% coverage per year may achieve HCV microelimination within 10 years, with minimal impact from additional OAT scale-up. Strategies based on mass initial HCV treatment (50 per 100 PWID the first year followed by 5 per 100 PWID thereafter) were most effective in settings with HCV prevalence of 60% or lower.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Scale-up of HCV TasP is the most effective strategy for microelimination of HCV. OAT scale-up, however, scale-up may be synergistic toward achieving microelimination goals when HCV prevalence exceeds 60% and when HCV treatment coverage is 10 per 100 PWID per year or lower.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa142","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T04:40:43Z","timestamp":1581655243000},"page":"755-763","source":"Crossref","is-referenced-by-count":19,"title":["Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States"],"prefix":"10.1093","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-037X","authenticated-orcid":false,"given":"Alexei","family":"Zelenev","sequence":"first","affiliation":[{"name":"AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"Li","sequence":"additional","affiliation":[{"name":"Institute for Community Research, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Portia","family":"Shea","sequence":"additional","affiliation":[{"name":"AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hecht","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L","family":"Altice","sequence":"additional","affiliation":[{"name":"AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA"},{"name":"Centre of Excellence for Research in AIDS, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,15]]},"reference":[{"key":"2021030519531540300_CIT0001","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"2021030519531540300_CIT0002","volume-title":"Global hepatitis report, 2017","author":"World Health Organization","year":"2017"},{"key":"2021030519531540300_CIT0003","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis C virus in the United States, 2003\u20132013","volume":"62","author":"Ly","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021030519531540300_CIT0004","doi-asserted-by":"crossref","first-page":"795","DOI":"10.15585\/mmwr.mm6618a2","article-title":"State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs \u2014 United States, 2015\u20132016","volume":"66","author":"Campbell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021030519531540300_CIT0005","volume-title":"Viral hepatitis surveillance\u2014United States, 2015","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"2021030519531540300_CIT0006","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"2021030519531540300_CIT0007","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2021030519531540300_CIT0008","first-page":"S1473","article-title":"Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study","volume":"17","author":"Zelenev","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021030519531540300_CIT0009","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"2021030519531540300_CIT0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The growing burden of mortality from viral hepatitis in the US, 1999\u20132007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"2021030519531540300_CIT0011","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatology"},{"key":"2021030519531540300_CIT0012","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/cid\/cit377","article-title":"Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements","volume":"57","author":"Grebely","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021030519531540300_CIT0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations","volume":"38","author":"Lazarus","year":"2018","journal-title":"Semin Liver Dis"},{"key":"2021030519531540300_CIT0014","first-page":"1094","article-title":"Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis","volume":"15","author":"Low","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021030519531540300_CIT0015","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021030519531540300_CIT0016","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"key":"2021030519531540300_CIT0017","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/cid\/civ894","article-title":"The impact of enhanced screening and treatment on hepatitis C in the United States","volume":"62","author":"Durham","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021030519531540300_CIT0018","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.27403","article-title":"The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs","volume":"60","author":"Hellard","year":"2014","journal-title":"Hepatology"},{"key":"2021030519531540300_CIT0019","article-title":"HIV and injection drug use: syringe services programs for HIV prevention","author":"Centers for Disease Control and Prevention","year":"2016"},{"key":"2021030519531540300_CIT0020","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1007\/s10461-017-1827-1","article-title":"Overlooked threats to respondent driven sampling estimators: peer recruitment reality, degree measures, and non-random selection","volume":"22","author":"Li","year":"2018;","journal-title":"AIDS Behav"},{"key":"2021030519531540300_CIT0021","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/liv.14152","article-title":"Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs","volume":"39","author":"Latham","year":"2019","journal-title":"Liver Int"},{"key":"2021030519531540300_CIT0022","author":"World Health Organization","year":"2012."},{"key":"2021030519531540300_CIT0023","volume-title":"HIV and viral hepatitis factsheet","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"2021030519531540300_CIT0024","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/aje\/kwz097","article-title":"Scaling up hepatitis C prevention and treatment interventions for achieving elimination in the United States: a rural and urban comparison","volume":"188","author":"Fraser","year":"2019","journal-title":"Am J Epidemiol"},{"key":"2021030519531540300_CIT0025","doi-asserted-by":"crossref","first-page":"e0206356","DOI":"10.1371\/journal.pone.0206356","article-title":"Combination interventions for hepatitis C and cirrhosis reduction among people who inject drugs: an agent-based, networked population simulation experiment","volume":"13","author":"Khan","year":"2018","journal-title":"PLoS One"},{"key":"2021030519531540300_CIT0026","doi-asserted-by":"crossref","first-page":"e78286","DOI":"10.1371\/journal.pone.0078286","article-title":"Hepatitis C transmission and treatment in contact networks of people who inject drugs","volume":"8","author":"Rolls","year":"2013","journal-title":"PLoS One"},{"key":"2021030519531540300_CIT0027","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1097\/QAI.0b013e318299c3f4","article-title":"Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia","volume":"63","author":"Vermund","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021030519531540300_CIT0028","volume-title":"Australia\u2019s progress towards hepatitis C elimination: annual report 2019","author":"Burnet Institute and Kirby Institute","year":"2019"},{"key":"2021030519531540300_CIT0029","first-page":"21","article-title":"Restricted access: State medicaid coverage of sofosbuvir hepatitis C treatment","volume-title":"J Leg Med","author":"Tumber","year":"2017"},{"key":"2021030519531540300_CIT0030","doi-asserted-by":"crossref","first-page":"22073","DOI":"10.1073\/pnas.0908366106","article-title":"Missing and spurious interactions and the reconstruction of complex networks","volume":"106","author":"Guimer\u00e0","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021030519531540300_CIT0031","volume-title":"National Health Behavioral Survey: Injection Drug Users","author":"Centers for Disease Control and Prevention","year":"2009"},{"key":"2021030519531540300_CIT0032","volume-title":"Diagnoses of HIV infection in the United States and dependent areas, 2015","author":"Centers for Disease Control and Prevention","year":"2016"},{"key":"2021030519531540300_CIT0033","article-title":"HIV and viral hepatitis","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"2021030519531540300_CIT0034","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/hep.25575","article-title":"Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution","volume":"55","author":"Liu","year":"2012","journal-title":"Hepatology"},{"key":"2021030519531540300_CIT0035","doi-asserted-by":"crossref","first-page":"ofx090","DOI":"10.1093\/ofid\/ofx090","article-title":"Spontaneous clearance of hepatitis C virus infection among human immunodeficiency virus-infected men who have sex with men","volume":"4","author":"Newsum","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2021030519531540300_CIT0036","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"2021030519531540300_CIT0037","article-title":"Trends in the use of methadone, buprenorphine and extended release naltrexone at substance abuse treatment facilities: 2003\u20132015 (update).","author":"Alderks","year":"2017"},{"key":"2021030519531540300_CIT0038","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5055\/jom.2007.0036","article-title":"Patterns of illicit drug use and retention in a methadone program: a longitudinal study","volume":"3","author":"Davstad","year":"2007","journal-title":"J Opioid Manag"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa142\/33165784\/ciaa142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/5\/755\/36415702\/ciaa142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/5\/755\/36415702\/ciaa142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T20:02:41Z","timestamp":1614974561000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/5\/755\/5736406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,15]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,15]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa142","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,2,15]]}}}